in vitro News and Research

RSS

Roche establishes strategic alliance with Diagnostic Laboratory Services

Roche announced today the establishment of a strategic alliance with Diagnostic Laboratory Services of Aiea, Hawaii, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.

From Roche Sequencing and Life Science 10 Aug 2015

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Ponatinib is highly active when given to patients within 6 months of developing chronic phase chronic myeloid leukaemia, phase II results show, but its toxicity profile is unacceptable for first-line treatment.

7 Aug 2015

Study may lead to effective antimicrobial treatment strategies for people with uncontrolled diabetes

Case Western Reserve scientists may have uncovered a molecular mechanism that sets into motion dangerous infection in the feet and hands often occurring with uncontrolled diabetes. It appears that high blood sugar unleashes destructive molecules that interfere with the body's natural infection-control defenses.

7 Aug 2015

NFIX protein drives NSC differentiation toward oligodendrocytes

An international team of researchers has shown that NFIX, a protein that regulates neuronal stem cell activity (NSC), also has a role in driving NSC differentiation toward oligodendrocytes, a type of glial cell. These cells produce the myelin that surrounds and protects neurons.

7 Aug 2015

In vitro testing provides proof of concept for osteopathic manipulative therapy

In vitro studies of the cellular effects of modeled osteopathic manipulative therapy (OMT) provide proof of concept for the manual techniques practiced by doctors of osteopathic medicine (DOs), according to researchers from the University of Arizona College of Medicine - Phoenix.

5 Aug 2015

Certain genes exposed to harsh environmental factors can increase diabetes risk

Arsenic, which can be present in ground water, modifies an enzyme that alters the secretion of insulin in the pancreas. Physicians, usually, show type II diabetes as a consequence of an exaggerated food intake and lack of exercise; however, there are about 50 genes that cause changes in the DNA, known as polymorphisms, that when combined with harsh environmental factors are at increased risk of developing the disease, mentioned PhD Marta Ostrosky Wegman, director of the Institute for Biomedical Research the National University of Mexico (UNAM).

5 Aug 2015

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

Australian pharmaceutical company Pharmaxis Ltd and UK biotechnology company Synairgen plc today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).

5 Aug 2015

New article explains why animal models are still essential to biological research

Future Science Group (FSG) today announced the publication of a new article in Future Science OA, covering the use of animal models in scientific research.

4 Aug 2015

Scientists develop artificial blood vessels that are resistant to blood clot formation

Scientists from ITMO University developed artificial blood vessels that are not susceptible to blood clot formation. The achievement was made possible by a new generation of drug-containing coating applied to the inner surface of the vessel.

4 Aug 2015

Novel 3D human skin tissue model could help detect presence of known skin sensitizers in medical device extracts

New research shows that exposing a 3D human skin tissue model to extracts of medical device materials can detect the presence of sensitizers known to cause an allergic response on contact in some individuals. Conventional skin sensitization testing of medical devices relies on animal testing, whereas human skin models could replace animal methods, according to an article in the new journal Applied In Vitro Toxicology, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

30 Jul 2015

Aeterna Zentaris selects optimized Erk inhibitor molecule for further development

Aeterna Zentaris Inc. today announced it has selected an optimized Erk inhibitor molecule for development, thus achieving another important milestone in the development of a new class of potential cancer therapies.

29 Jul 2015

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

LMU researchers reveal role of mutations in development of Ewing's sarcoma

Researchers from Ludwig-Maximilians-Universitaet in Munich have elucidated at the molecular level how an otherwise innocuous inherited mutation that is quite common in European populations interacts with a spontaneous somatic mutation to promote the development of Ewing's sarcoma.

28 Jul 2015

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

Innovative approach to treating AAT deficiency

Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin (AAT)--which is missing or nonfunctional in the genetic disorder AAT deficiency--into cells in the laboratory, enabling the cells to produce highly functional AAT.

28 Jul 2015

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a very aggressive form of pulmonary fibrosis and has a particularly poor prognosis. This fatal disease, for which so far no causal therapies exist, is characterized by a massive deposition of connective and scar tissue in the lung, which leads to a progressive loss of lung function and ultimately death.

28 Jul 2015

Corgenix Medical to present several scientific abstracts at 2015 AACC Clinical Lab Expo

Corgenix Medical Corporation, the U.S. - based operation of ORGENTEC Diagnostika, is presenting several scientific abstracts at the 2015 American Association for Clinical Chemistry Clinical Lab Expo in Atlanta. Three abstracts involve the ReEBOV Ebola rapid diagnostic test (RDT) with a fourth abstract involving the AtherOx™ Assay for assessing heart disease risk.

25 Jul 2015

in vitro News and Research

Roche establishes strategic alliance with Diagnostic Laboratory Services

Vascular side effects prevent first-line ponatinib use in chronic phase CML

Study may lead to effective antimicrobial treatment strategies for people with uncontrolled diabetes

NFIX protein drives NSC differentiation toward oligodendrocytes

In vitro testing provides proof of concept for osteopathic manipulative therapy

Certain genes exposed to harsh environmental factors can increase diabetes risk

Pharmaxis, Synairgen partner to develop LOXL2 inhibitor to treat idiopathic pulmonary fibrosis

New article explains why animal models are still essential to biological research

Scientists develop artificial blood vessels that are resistant to blood clot formation

Novel 3D human skin tissue model could help detect presence of known skin sensitizers in medical device extracts

Aeterna Zentaris selects optimized Erk inhibitor molecule for further development

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

LMU researchers reveal role of mutations in development of Ewing's sarcoma

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Innovative approach to treating AAT deficiency

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Corgenix Medical to present several scientific abstracts at 2015 AACC Clinical Lab Expo

Bosutinib resistance linked to ABCB1 transporter

EKF Diagnostics launches new clinical chemistry analyzer at AACC 2015

Study shows glitazone antidiabetic drug may reduce risk of Parkinson’s disease

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News